Short Bowel Syndrome-Pipeline Review, H2 2016

Short Bowel Syndrome-Pipeline Review, H2 2016


  • Products Id :- GMDHC8806IDB
  • |
  • Pages: 61
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Short Bowel Syndrome-Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Short Bowel Syndrome-Pipeline Review, H2 2016, provides an overview of the Short Bowel Syndrome (Gastrointestinal) pipeline landscape.

Short bowel syndrome is a complex disease that occurs due to the physical loss or the loss of function of a portion of the small and/or large intestine. Symptoms include bloating, cramping, fatigue, heartburn, vomiting, weakness and diarrhea. Complications of short bowel syndrome include malnutrition, peptic ulcers, kidney stones and small intestinal bacterial overgrowth. Treatment includes vitamin and mineral supplements, antibiotics, proton pump inhibitors and bile-salt binders.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Short Bowel Syndrome-Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Short Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Short Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Short Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 1 and 5 respectively.Short Bowel Syndrome.

Short Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Short Bowel Syndrome (Gastrointestinal).

The pipeline guide reviews pipeline therapeutics for Short Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Short Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Short Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Short Bowel Syndrome (Gastrointestinal)

Reasons To Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Short Bowel Syndrome (Gastrointestinal).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Short Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Short Bowel Syndrome Overview 7

Therapeutics Development 8

Pipeline Products for Short Bowel Syndrome-Overview 8

Short Bowel Syndrome-Therapeutics under Development by Companies 9

Short Bowel Syndrome-Pipeline Products Glance 10

Late Stage Products 10

Clinical Stage Products 11

Early Stage Products 12

Short Bowel Syndrome-Products under Development by Companies 13

Short Bowel Syndrome-Companies Involved in Therapeutics Development 14

Ardelyx Inc 14

Naia Ltd 15

Nutrinia Ltd 16

OxThera AB 17

Sancilio & Company Inc 18

Shire Plc 19

Tasly Pharmaceutical Group Co Ltd 20

Zealand Pharma AS 21

Short Bowel Syndrome-Therapeutics Assessment 22

Assessment by Monotherapy Products 22

Assessment by Target 23

Assessment by Mechanism of Action 25

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Drug Profiles 31

glepaglutide-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

GXG-8-Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

NB-1001-Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

NB-1002-Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

NTRA-9620-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

Oxabact-Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

RDX-98940-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

SC-403-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

teduglutide-Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

Short Bowel Syndrome-Dormant Projects 46

Short Bowel Syndrome-Discontinued Products 47

Short Bowel Syndrome-Product Development Milestones 48

Featured News & Press Releases 48

Nov 29, 2016: Naia Rare Diseases Announces Investigational New Drug Application Submission to Initiate Clinical Trials of NB 1001 for Short Bowel Syndrome 48

Jul 07, 2016: Shire Receives Extension of Market Authorization in Europe for Revestive (Teduglutide) for the Treatment of Paediatric Patients with Short Bowel Syndrome (SBS) 48

May 27, 2016: Shire Receives Positive CHMP Opinion in Europe for Revestive (Teduglutide) for Paediatric Patients with Short Bowel Syndrome 49

Feb 15, 2016: Zealand doses the first patients with ZP1848 for short bowel syndrome, advancing the second of its proprietary specialty medicines into Phase II development in 2016 50

Oct 20, 2015: NAIA Rare Diseases a subsidiary of NAIA, Receives Orphan Drug Designation from U.S. FDA for NB1001 for the Treatment of Short Bowel Syndrome 51

Oct 12, 2015: Naia Successfully Completes Pre-IND Meeting with U.S. FDA for NB1001, Long-Acting GLP-1 Receptor Agonist for Treatment of Short Bowel Syndrome 51

Sep 17, 2015: Zealand advances its proprietary, long-acting GLP-2 analogue, ZP1848, into clinical Phase II development for the treatment of Short Bowel Syndrome 52

Apr 06, 2015: Shire Comments on USPTO Petition Related to GATTEX 53

Nov 24, 2014: Teduglutide Granted Orphan Drug Designation in Japan 53

Sep 23, 2014: Oxabact Granted EMA Orphan Drug Designation for Treatment of SBS 54

Jun 30, 2014: FDA Approves Updated Labeling for Gattex (Teduglutide) for Injection to Include Long-Term Data 54

Jan 02, 2014: NPS Pharmaceuticals Initiates Global Registration Study of Teduglutide in Pediatric Patients with Short Bowel Syndrome 55

Nov 13, 2013: NPS Pharmaceuticals Announces FDA Acceptance of Supplemental New Drug Application for Gattex for Injection 56

Oct 14, 2013: New Data from STEPS 2 Support the Long Term Use of Gattex for Injection in Adult Patients with Short Bowel Syndrome 57

Oct 02, 2013: NPS Pharmaceuticals Reports Gattex STEPS 2 Study to be Presented at American College of Gastroenterology Meeting 58

Appendix 60

Methodology 60

Coverage 60

Secondary Research 60

Primary Research 60

Expert Panel Validation 60

Contact Us 60

Disclaimer 61

List of Figures

Number of Products under Development for Short Bowel Syndrome, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 11

Assessment by Monotherapy Products, H2 2016 22

Number of Products by Targets, H2 2016 23

Number of Products by Stage and Targets, H2 2016 23

Number of Products by Mechanism of Actions, H2 2016 25

Number of Products by Stage and Mechanism of Actions, H2 2016 25

Number of Products by Routes of Administration, H2 2016 27

Number of Products by Stage and Routes of Administration, H2 2016 27

Number of Products by Molecule Types, H2 2016 29

Number of Products by Stage and Molecule Types, H2 2016 29

List of Tables

Number of Products under Development for Short Bowel Syndrome, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Short Bowel Syndrome-Pipeline by Ardelyx Inc, H2 2016 14

Short Bowel Syndrome-Pipeline by Naia Ltd, H2 2016 15

Short Bowel Syndrome-Pipeline by Nutrinia Ltd, H2 2016 16

Short Bowel Syndrome-Pipeline by OxThera AB, H2 2016 17

Short Bowel Syndrome-Pipeline by Sancilio & Company Inc, H2 2016 18

Short Bowel Syndrome-Pipeline by Shire Plc, H2 2016 19

Short Bowel Syndrome-Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2016 20

Short Bowel Syndrome-Pipeline by Zealand Pharma AS, H2 2016 21

Assessment by Monotherapy Products, H2 2016 22

Number of Products by Stage and Target, H2 2016 24

Number of Products by Stage and Mechanism of Action, H2 2016 26

Number of Products by Stage and Route of Administration, H2 2016 28

Number of Products by Stage and Molecule Type, H2 2016 30

Short Bowel Syndrome-Dormant Projects, H2 2016 46

Short Bowel Syndrome-Discontinued Products, H2 2016 47

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Ardelyx Inc, Naia Ltd, Nutrinia Ltd, OxThera AB, Sancilio & Company Inc, Shire Plc, Tasly Pharmaceutical Group Co Ltd, Zealand Pharma AS

Short Bowel Syndrome Therapeutic Products under Development, Key Players in Short Bowel Syndrome Therapeutics, Short Bowel Syndrome Pipeline Overview, Short Bowel Syndrome Pipeline, Short Bowel Syndrome Pipeline Assessment

select a license

Single User License
USD 2000 INR 128700
Site License
USD 4000 INR 257400
Corporate User License
USD 6000 INR 386100

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com